Theravance Biopharma
TBPH
81 hedge funds and large institutions have $525M invested in Theravance Biopharma in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 12 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
24% more capital invested
Capital invested by funds: $425M → $525M (+$100M)
21% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $920K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 83 → 81 (-2)
Top Buyers
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$28.8M |
| 2 |
AC
Armistice Capital
New York
|
+$6.54M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.56M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$1.51M |
Top Sellers
| 1 |
SAM
Scion Asset Management
Saratoga,
California
|
-$2.64M |
| 2 |
D.E. Shaw & Co
New York
|
-$2M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.23M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.13M |
| 5 |
Millennium Management
New York
|
-$1.03M |
TBPH Hedge Fund Activity: Q1 2016 in Review
81 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2016, worth a combined $525M — up 24% from $425M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TBPH and 11 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 31 added.
The largest buyer was Woodford Investment Management, adding an estimated $28.8M. The largest seller was Scion Asset Management, cutting an estimated $2.64M.
- 81 institutional investors held Theravance Biopharma (TBPH) as of Q1 2016, down from 83 in Q4 2015.
- Funds reported $525M of Theravance Biopharma stock for Q1 2016, up 24% quarter-over-quarter.
- 11 funds opened new Theravance Biopharma positions in Q1 2016 and 12 closed out, a net change of -1 holder.
- The largest Theravance Biopharma buyer in Q1 2016 was Woodford Investment Management, an estimated $28.8M added.
- The largest Theravance Biopharma seller in Q1 2016 was Scion Asset Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2016.